Saturday , 22 February 2025
0

No products in the cart.

Worldwide News Worldwide News
0

No products in the cart.

Home Health Roche Welcomes FDA Approvals for Injectable Versions of MS and Cancer Drugs
Health

Roche Welcomes FDA Approvals for Injectable Versions of MS and Cancer Drugs

September 15, 20241 Mins read55 Views
Roche Welcomes FDA Approvals for Injectable Versions of MS and Cancer Drugs

Roche’s Tecentriq Hybreza is a subcutaneously injectable formulation of the cancer drug Tecentriq while Ocrevus Zunovo is an injectable version of multiple sclerosis drug Ocrevus. Each is administered in minutes compared to an hour or more for infused therapies.

The post Roche Welcomes FDA Approvals for Injectable Versions of MS and Cancer Drugs appeared first on MedCity News.

Previous post

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles

A paper by Proudman et al. (2024) finds that doing so would...

ByFebruary 22, 2025
Health

Carlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird...

ByFebruary 21, 2025

This fact sheet provides an overview of the history of the Kemp-Kasten...

ByFebruary 21, 2025

Katherine Saunders is the co-founder and CMO at FlyteHealth. She was one...

ByFebruary 21, 2025

Abous us

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis

Subscribe Now

    Subscribe to our mailing list to receives daily updates direct to your inbox!
    © Copyright 2022 Jellywp. All rights reserved powered by Jellywp.com